Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Cambridge, UK, 29th April 2013: Kymab, a monoclonal antibody biopharmaceutical company, announced today that Dr. Allan Bradley, Chief Scientific Officer of Kymab, will present data from the new Kymouse HL™ transgenic human antibody mouse. The presentation will describe how use of the new Kymouse HL strain in combination with the existing Kymouse HK™ strain can improve antibody drug discovery by generating highly selective, potent, human antibody drug candidates. The invited presentation will be made at the Biologics Partnering Forum at PEGS 2013 in Boston, USA on Monday 29th of April at 10:45am local time.
Kymouse is a series of transgenic human antibody mouse strains designed to generate high quality, fully human, therapeutic antibodies with minimal requirement for subsequent antibody engineering. The Kymouse HL strain produces antibodies with human heavy and lambda light chains whereas Kymouse HK generates antibodies with human heavy and kappa light chains. By using both strains in combination, the diversity of the human antibody pool available for screening will be significantly increased.
Dr. Allan Bradley, Chief Scientific Officer of Kymab, said: “The addition of the Kymouse HL strain to the Kymouse platform allows us to generate antibody panels with a full representation of kappa and lambda light chains. We have demonstrated that both Kymouse HK and HL strains have a normal immune response and produce high antibody titres of all isotypes following immunisation. The divergent biophysical properties of the lambda and kappa light chains are expected to enable discovery of antibodies with different epitope coverage in the two strains.”
Andrew Sandham, Chief Executive Officer, said: “Building out Kymouse with the addition of the Kymouse HL strain offers significant additional benefits to drug discovery teams. Lambda light chains can be important in a therapeutic setting, with certain FDA approved therapeutic antibodies containing lambda rather than kappa light chains. Kymouse HK and HL strains provide an efficient way for researchers to generate diverse populations of both kappa and lambda light chain antibodies to maximise the probability of finding the best drug candidate for each target. ”
About Kymab
Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.
Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.
Founded in 2009, Kymab raised £20m of equity financing in 2010 from the investment division of the Wellcome Trust. It has an experienced management team with a successful track record in drug discovery and development.
For further information, please visit www.kymab.com
Contact Kymab:
Andrew Sandham, Chief Executive Officer
Tel: +44 (0)1223 833301, Email: andrew.sandham@kymab.com
M: Communications
Mary Clark
Tel: +44 (0)20 7920 2361, Email: kymab@mcomgroup.com
Help employers find you! Check out all the jobs and post your resume.
